E ndothelin (ET)-1 was first described as a potent vasoconstrictor peptide. 1 The primary source of ET-1 is vascular endothelial cells (ECs), but it is also produced by other cell types.
importance of eET-1 in BP regulation. Indeed, plasma ET-1 was reduced by 80% and systolic BP by ≈10 mm Hg in mice with EC-restricted ET-1 gene disruption. 13 Moreover, we have shown using tamoxifen-inducible EC-restricted human ET-1 overexpressing (ieET-1) mice that after a 3-week induction, BP rises in an ET A receptor-dependent manner.
14 However, ieET-1 mice did not develop vascular or renal injury.
We hypothesized that a longer exposure to eET-1 overexpression and sustained BP rise may be necessary to cause vascular and kidney injury. To test this hypothesis, we determined whether 3-month (long term) exposure to eET-1 overexpression will cause sustained BP rise and vascular and renal damage. In addition, oxidative stress and immune cell infiltration were examined because they have been implicated in the development of small artery dysfunction, remodeling, and stiffening that result in elevated peripheral resistance and finally lead to target-organ damage, such as renal injury. [15] [16] [17] [18] [19] 
Methods
Detailed Methods are available in the online-only Data Supplement.
Experimental Design
This study was approved by the Animal Care Committee of the Lady Davis Institute for Medical Research and McGill University, followed recommendations of the Canadian Council for Animal Care, and was in agreement with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health. Control mice expressing a tamoxifen-inducible Cre recombinase 20 under the control of endothelium-specific Tie2 promoter (named hereafter ieCre) and ieET-1 mice have been described previously 14, 21 and were generated in our animal facility. The endothelial specificity of tamoxifen-induced Cre recombination was demonstrated previously 14 in mesenteric arteries (MAs), aorta, heart, liver, and kidney using ieCre mice crossed with ROSA26 mT-mG/+ reporter mice, which expressed a loxP-flanked, membrane-targeted tandem dimer tomato (mT), before Cre-mediated excision, and a membranetargeted enhanced green fluorescent protein (mG) after excision, under the control of the CMV enhancer/chicken β-actin promoter driving the expression in all cell types. Nine-to-12-week-old male ieCre and ieET-1 mice were treated with tamoxifen (1 mg/d, subcutaneously) for 5 days and studied 3 months later. As described previously, 14 24 -hour urine was collected using metabolic cages to determine urinary albumin and creatinine in the week before or after the third month, and renal artery flow was determined using ultrasound the following day. At the end of the protocol, mice were weighed, anesthetized with isoflurane, and blood was collected by cardiac puncture on EDTA for plasma ET-1 determination. The MA vascular bed was harvested with the intestine in ice-cold Krebs solution. The heart, lung, kidneys, and right tibia were harvested in ice-cold PBS. Tissues were weighed and tibia length determined. The right kidney was used for immune cell profiling by flow cytometry. Second-order MA was used for determination of endothelial function and vascular mechanics by pressurized myography. Sections of MAs with perivascular adipose tissue (PVAT) and the left kidney were embedded in VWR Clear Frozen Section Compound (VWR International, Edmonton, Alberta, Canada) for determination of reactive oxygen species (ROS) production, fibronectin, MCP-1 (monocyte chemoattractant protein-1), or KIM-1 (kidney injury molecule-1) expression or monocyte/macrophage and T-cell infiltration by immunofluorescence. Sections of MAs and left kidney were fixed in 4% paraformaldehyde in PBS for 48 hours at 4°C and embedded in paraffin for investigation of collagen content with Sirius red staining, kidney injury using Masson trichrome, and Periodic Acid Schiff staining or immune cell infiltration using CD45 immunohistochemistry.
In a subgroup of tamoxifen-treated ieCre and ieET-1 mice, BP was determined by telemetry as described previously. 22 BP was assessed during the last 2 days of the third-month period, and thereafter, mice were studied as above.
Another subset of tamoxifen-treated ieET-1 mice was treated with the ET A receptor blocker, atrasentan (10 mg·kg −1 ·d −1 PO) mixed with the food, during the last 2 weeks of the third month. BP was determined by telemetry 2 days before and during atrasentan treatment, and thereafter, mice were studied as above.
A separate group of ieCre and ieET-1 mice treated with or without atrasentan was used to examine the long-term effects of eET-1 overexpression on the expression of ET A (Ednra) and ET B (Ednrb) receptors, Col1A1 (collagen type I alpha 1) and Col3A1 (collagen type III alpha 1), and Ren1 (renin) in MAs or kidney by reverse transcription/ quantitative polymerase chain reaction.
Data Analysis
Results are presented as means±SEM. Data were compared with 2-way ANOVA for repeated measures or 1-way ANOVA, with all ANOVA tests followed by a Student-Newman-Keuls post hoc test or with an unpaired t test, as appropriate. Correlations were evaluated with a Pearson test. P<0.05 was considered statistically significant.
Results

Long-Term Induction of Endothelial Human ET-1 Overexpression Increased Plasma ET-1 Levels and BP in ET A Receptor-Dependent Manner
Three months after tamoxifen injections, plasma ET-1 levels were 11-fold higher in ieET-1 mice compared with ieCre mice and were unaffected by ET A receptor blockade with atrasentan ( Figure S1 in the online-only Data Supplement). Mean hour systolic BP and diastolic BP were 22 and 16 mm Hg higher, respectively, and heart rate unchanged in ieET-1 mice compared with ieCre mice ( Figure 1A ; Figure  S2A and S2B). The BP elevation was ET A receptor-dependent because treatment with atrasentan reversed nighttime and daytime systolic BP elevation in ieET-1 mice ( Figure 1B ). Diastolic BP tended to be lower, whereas heart rate was unchanged in atrasentan-treated ieET-1 compared with control ieET-1 mice ( Figure S2C and S2D ). Body weight, heart, lung, and kidney weight were unaffected by the long-term induction of eET-1 overexpression or atrasentan treatment (Table S1 ).
Long-Term Induction of Endothelial Human ET-1 Overexpression Induced Mesenteric Artery Endothelium Dysfunction
Contractile responses to norepinephrine were similar between groups ( Figure S3A ). Maximal relaxation response to acetylcholine in vessels precontracted with norepinephrine was decreased by 48% in ieET-1 mice compared with ieCre mice and was not corrected by atrasentan treatment (Figure 2A ). Vasodilatory responses to acetylcholine were completely abrogated by the NO synthase inhibitor N ω -nitro-l-arginine methyl ester in all groups ( Figure S3B ), indicating that NO was the major mediator of the vasodilator response. Endotheliumindependent relaxation responses to the NO donor, sodium nitroprusside, were similar in all groups ( Figure S3C ), suggesting that MA vasodilatory impairment was not because of a vascular smooth muscle defect.
Long-Term Induction of Endothelial Human ET-1 Overexpression Caused Mesenteric Artery Stiffening
eET-1 overexpression caused MA stiffening in ieET-1 mice, as indicated by a leftward displacement of the stress-strain curves compared with ieCre mice ( Figure 2B ). Vascular stiffening was normalized by treatment with atrasentan. In contrast, longterm exposure to eET-1 overexpression did not cause vascular remodeling because MA media/lumen and media cross-sectional area were similar in all groups ( Figure S3D and S3E).
Long-Term Induction of Endothelial Human ET-1 Overexpression Increased Oxidative Stress in PVAT of Mesenteric Arteries
To explain the endothelial dysfunction, ROS generation was studied in the media and PVAT of MA. ROS generation was unaltered in MA media but increased 1.4-fold in the MA PVAT (Figure 2C and 2D; Figure S4 ). Atrasentan treatment of ieET-1 decreased MA ROS generation by 47% compared with ieCre mice and reversed the eET-1-induced elevation in PVAT ROS generation.
Long-Term Induction of Endothelial Human ET-1 Overexpression Increased Mesenteric Artery Collagen Expression
To investigate the mechanisms leading to vascular stiffening, fibronectin expression and collagen content were assessed in MAs. Fibronectin expression in MA wall was similar in MA relaxation responses to acetylcholine (A) and stress-strain relationships (B) by pressurized myography, reactive oxygen species generation by dihydroethidium (DHE) fluorescence in MA media and perivascular adipose tissue (PVAT; C), and collagen type I alpha 1 (Col1a1; D) and III alpha 1 (Col3a1; E) expression in MA by reverse transcription/quantitative polymerase chain reaction were assessed in tamoxifen-treated inducible endothelium-restricted Cre recombinase (ieCre) and human endothelin-1 overexpressing (ieET-1) mice treated with or without atrasentan (Atras). Data are presented as means±SEM, n=7 for ieCre, 11 for ieET-1, and 9 for ieET-1+Atras in (A); 8 for ieCre and 9 for ieET-1 and ieET-1+Atras in (B); 9 for ieCre+vehicle (Veh), 8 for ieET-1+Veh, and 6 for ieET1+Atras in (C); and 5 for ieCre+Veh, 8 for ieET-1+Veh, and 7 for ieET-1+Atras in (D) and (E). Data were analyzed using 2-way ANOVA for repeated measures in (A) and 1-way ANOVA in (B-E), with all ANOVA followed by a Student-Newman-Keuls post hoc test. The displacement of the stress-strain curves was analyzed by comparing the strain at 140 mm Hg in (B).*P<0.05 vs ieCre, †P<0.05 vs ieET-1.
ieCre and ieET-1 mice ( Figure S5 ). Quantification of the Sirius red-stained mesenteric artery polarized images did not reveal changes in collagen content in the adventitia and media ( Figure S6 ) in ieET-1 compared with ieCre mice. However, because the collagen content in the media was at the limit of detection, collagen was also determined at mRNA level in MAs. Col1a1 and Col3a1 mRNA expression were increased 2.5-and 1.8-fold, respectively, in ieET-1 compared with ieCre mice (Figure 2D and 2E) . Col1a1 mRNA expression was similar, whereas Col3a1 mRNA expression tended to be lower in atrasentan-treated ieET-1 compared with ieET-1 mice. MA mRNA expression of ET A and ET B receptors was unaffected at 3 months of induction of eET-1 overexpression or by atrasentan treatment ( Figure S7 ).
Long-Term Induction of Endothelial Human ET-1 Overexpression Increased Monocyte/Macrophage Infiltration in the PVAT of Mesenteric Arteries
Vascular inflammation was investigated by determining the expression of MCP-1 in the vascular wall and the infiltration of monocyte/macrophages and T cells in the MA PVAT. MA wall MCP-1 expression was similar in all the groups ( Figure S8 ). Monocyte/macrophage infiltration was 1.5-fold higher in ieET-1, which was reversed by atrasentan treatment ( Figure 3A ; Figure S9A ). On the contrary, CD3
+ T-cell infiltration was similar in all groups ( Figure 3B ; Figure S9B ).
Long-Term Induction of Endothelial Human ET-1 Overexpression Decreased Renal Artery Flow
To determine the contribution of the kidney in eET-1-induced BP rise, renal artery flow and renal mRNA expression of Ren1, Ednra, and Ednrb were assessed. Long-term eET-1 overexpression decreased renal artery flow by 42%, which was not corrected by atrasentan treatment compared with ieCre mice (Table S2 ). This change was not because of an alteration in renal artery diameter and heart rate. The mRNA expression levels of renal Ednra and Ednrb and renal cortex Ren1 were similar in ieCre and ieET-1 mice ( Figure S10 ). Plasma creatinine was similar in all groups ( Figure S11A ), which suggests that the decrease in renal artery flow was not associated with a reduction in glomerular filtration rate.
Long-Term Induction of Endothelial Human ET-1 Overexpression Caused Early Renal Damage and Inflammation
To evaluate renal injury, KIM-1 expression, which is upregulated in proximal tubular epithelium in kidney injury, 23 Masson trichrome-, and Periodic Acid Schiff-stained kidney sections and urine albumin were examined. KIM-1 expression was increased 4-fold in renal cortex tubules of ieET-1 compared with ieCre mice, and this increase was corrected by atrasentan treatment ( Figure 4A and 4B) . However, no obvious renal Data are presented as means±SEM, n=11 for ieCre and ieET1+vehicle (Veh) and 6 for ieET-1+Atras in (A and B) and 6 for ieCre and ieET-1+Veh and 7 for ieET-1+Atras in (C). Data were analyzed using 1-way ANOVA followed by a Student-NewmanKeuls post hoc test. *P<0.001 vs ieCre, †P<0.01 vs ieET-1.
lesions were detected on Masson trichrome-or Periodic Acid Schiff-stained kidney sections ( Figure S12 ). Furthermore, urinary albumin/creatinine ratio and albumin excretion were similar in all groups ( Figure 4C ; Figure S11B ).
Early renal injury was accompanied by immune cell infiltration. Examination of the CD45 immunohistochemically stained sections revealed increased CD45 + cell infiltration in the interstitial space and in glomeruli in ieET-1 compared with ieCre mice, which was reversed by atrasentan treatment ( Figure  S13 ). The infiltration of immune cells was further investigated by flow cytometry. The frequency and number of immune cells (CD45 + ) were increased 2.1-fold and 3.4-fold, respectively, in the kidney of ieET-1 compared with ieCre mice (Figure 5A and 5B; Figure S14A) Figure S14B and S14C). The frequency of these cells was similar in all groups. However, the number of infiltrating myeloid cells and myeloid-derived suppressive cells was increased >4-fold in the kidney of ieET-1 compared with ieCre ( Figure 5C through 5F ). In addition, the frequency of myeloid and nonimmune (CD45 − ) cells expressing the proinflammatory typical pattern-recognition receptor CD36, which has been involved in chronic kidney disease, [24] [25] [26] [27] [28] was examined. CD36 was detected in 7.5% of myeloid cells and 3% of nonimmune cells in ieCre mice (Figure 6A through 6D). The frequencies of myeloid and nonimmune (kidney) cells expressing CD36 were increased 3-and 1.5-fold, respectively, in the kidney of ieET-1 animals compared with ieCre mice and were reduced and reversed, respectively, by atrasentan. Furthermore, a high correlation between the frequency of CD36 + nonimmune cells and infiltrating immune cells was observed ( Figure 6E ), which suggests a role for CD36 in the renal inflammatory process. Interestingly, atrasentan treatment of ieET-1 mice reduced or reversed the infiltration of all studied immune cells and reversed the increased frequency of CD36 + kidney expressing cells ( Figures 5 and 6A through 6D ).
Discussion
In this study, we demonstrate that a 3-month induction of human eET-1 overexpression in mice resulted in sustained BP elevation, resistance artery endothelial dysfunction, and stiffening, associated with increased MA collagen mRNA expression, PVAT oxidative stress, and monocyte/macrophage infiltration. Furthermore, long-term exposure to eET-1 overexpression resulted in early renal damage and immune cell infiltration in the kidney. Except for MA endothelial dysfunction and collagen mRNA expression, all the above were reversed or reduced by 2 weeks of treatment with the ET A antagonist atrasentan.
In our initial study of ieET-1 mice, we observed that BP progressively rose during the 3 weeks after induction of eET-1 overexpression, in the absence of development of vascular injury.
14 This was in contrast to our previous findings using a constitutive eET-1 transgenic mouse model, which presented endothelial dysfunction and vascular remodeling in absence of BP rise. 29 We have postulated that the different phenotypes observed might be because of developmental effects or adaptation to life-long exposure to elevated ET-1 circulating or tissue levels. 14 We have also hypothesized that longer exposure to eET-1 overexpression is required to induce vascular injury, which is demonstrated in the present study. However, ieET-1 mice presented a different phenotype from the constitutive eET-1 overexpressing mice 29 because the BP remained elevated and there was no vascular remodeling after the 3-month induction of eET-1 overexpression. This was not because of different eET-1 overexpression levels because similar plasma ET-1 levels were observed using both constitutive eET-1 overexpressing mice previously 29 and ieET-1 mice in this study. The difference between the 2 models may be because of the fact that the ieET-1 mice are devoid of confounding developmental effects because eET-1 is not expressed in utero but induced in the adult mice. In addition, this study also showed that most of the long-term eET-1 overexpression effects, except for MA endothelial dysfunction, could be reversed or reduced by the ET A receptor blocker atrasentan during the last 2 weeks of the study. Threemonth eET-1 overexpression might have caused irreversible damage to the endothelium that could not be corrected by atrasentan, at least not in the 2 weeks examined. Perhaps continuation of the atrasentan treatment for a longer time could prevent further vascular injury because it attenuated or eliminated other factors, such as, elevated BP, oxidative stress, and immune cell infiltration. It should be noted that MA expression of ET receptors was unaffected by long-term exposure to eET-1 overexpression, whereas ET receptors were downregulated after a 3-week exposure to eET-1 overexpression. 14 This might represent an adaptation to the 3-month exposure to eET-1 overexpression. Altogether, the results indicate that ieET-1 may be a better model to study the role of endothelial-derived ET-1 in hypertension and vascular remodeling. Furthermore, our results showed that eET-1 plays an important role in the development and maintenance of hypertension in an ET A receptor-dependent manner.
Long-term induction of eET-1 overexpression had vascular effects that were limited to MA stiffening, which was corrected by atrasentan treatment. The increase in stiffness was not explained by changes in media fibronectin expression or adventitia and media collagen content but was associated with increased mRNA expression of Col1a1 and Col3a1. Whether these changes explain the MA stiffening is unclear because Col1a1 and Col3a1 mRNA expressions were not significantly reduced by atrasentan treatment. Alternatively, vascular stiffening could be explained by changes in vascular smooth muscle cells. Sehgel et al 30 showed that aortic stiffening could result in SHR from increases in vascular smooth muscle cell stiffness and adhesion properties in absence of aortic collagen and elastin changes, which could play a role here, but this requires further study.
The absence of vascular remodeling might be expected considering that the level of BP elevation achieved in + and CD45 + cells (E) was determined. Data are presented as means±SEM, n=6 for ieCre and ieET-1+vehicle (Veh) and 5 for ieET-1+Atras. Data were analyzed using 1-way ANOVA followed by a Student-NewmanKeuls post hoc test. *P<0.05 vs ieCre, †P<0.05 vs ieET-1.
tamoxifen-induced ieET-1 mice was moderate. In fact, a role of ET-1 in vascular remodeling was demonstrated previously in animal models of hypertension presenting greater BP elevation, including DOCA-salt uninephrectomized rats, 9 DOCAsalt rats, 10 and stroke-prone SHR. 12 Furthermore, d'Uscio et al 10 demonstrated a correlation between vascular remodeling and systolic BP with pressure values between ≈150 and ≈200 mm Hg.
It is well recognized nowadays that innate and adaptive immune systems contribute to hypertension, endothelial dysfunction, and vascular remodeling. 19, 31 Both monocyte/ macrophage and T lymphocyte perivascular infiltration have been observed in animal models of hypertension. Long-term induction of eET-1 overexpression may have resulted in the initiation of the inflammatory response because only monocyte/macrophage perivascular infiltration was observed. Furthermore, the extent of monocyte/macrophage infiltration was smaller in ieET-1 mice compared with angiotensin II or aldosterone-infused mice. 22, 32 This and the lack of T-cell infiltration could be explained, at least in part, by the absence of increase in MCP-1 expression because this chemokine has been demonstrated to attract not only monocytes but also T cells. 33, 34 Nevertheless, the perivascular infiltrating monocyte/ macrophages could have contributed to the development of endothelial dysfunction and vascular stiffness in ieET-1 mice. ET-1 might represent 1 component of a multifactorial system involved in development of hypertension and vascular injury in animal models and in humans. This hypothesis might be confirmed by combining the induction of eET-1 overexpression with other hypertensive stimuli.
The kidneys play a key role in BP regulation and hypertension. 35 Long-term induction of eET-1 overexpression may raise BP through a direct action on renal microvascular resistance through activation of ET receptors. 36 Indeed, a decrease in renal artery flow was observed in ieET-1 mice. However, this was not observed 3 weeks after the induction of eET-1 overexpression.
14 Therefore, the kidneys could play a role in the maintenance but not in the initiation of ET-1-induced BP elevation. The reduction in renal artery flow was not corrected by atrasentan, which could be because of the tight attachment and remaining action of eET-1 on renal ET B receptors that could mediate efferent vasoconstriction when ET-1 levels reach 1 to 10 nmol/L. 36 Similarly to the short-term ieET-1 overexpression study, 14 Ren1 seems not to be implicated in eET-1-induced sustained BP elevation. In contrast to the short-term ieET-1 overexpression study, renal ET receptor expression was unaffected by long-term induction of eET-1 overexpression, which suggests renal adaptation of ET receptors to long-term exposure to eET-1 overexpression.
Long-term induction of eET-1 overexpression caused early renal injury and immune cell infiltration. The early renal injury was demonstrated by the increased expression of KIM-1 in renal cortex tubules, accompanied, however, by undetectable histological lesions as shown by Masson trichrome or Periodic Acid Schiff staining and absence of increased urinary albumin excretion. KIM-1 is a phosphatidylserine and scavenger receptor that is expressed in injured tubular epithelial cells early in the development of renal proximal tubule injury. 37 Increased expression of KIM-1 transforms epithelial cells into semiprofessional phagocytes that eliminate apoptotic and necrotic cellular debris, thus limiting the inflammatory response. 23, 38 Furthermore, it has been recently shown that recombinant KIM-1 may activate macrophages in vitro. 39 Renal infiltrating immune cells are made up in large part of myeloid cells and of a myeloid cell subpopulation, myeloid-derived suppressive cells. Myeloid-derived suppressive cells are anti-inflammatory cells that have been shown to be increased in the blood and the spleen in murine models of hypertension and in the kidney in a model of acute kidney injury. 40, 41 We observed an increase in the fraction of myeloid cells and kidney nonimmune cells expressing the proinflammatory B scavenger/pattern-recognition receptor CD36, which could contribute to the development of kidney injury. 26, 28, 42 Cd36 knockout protects high-fat diet-fed Apoe −/− mice 25 and mice with 5/6 nephrectomy infused with angiotensin II from development of renal injury and immune cell infiltration. 25, 27 Furthermore, antagonism of CD36 by 5A peptide protects mice with 5/6 nephrectomy infused with angiotensin II and CD-1 mice with unilateral ureteral obstruction.
27 CD36 can bind a broad range of ligands, including ApoA-1 (apolipoprotein A-1), thrombospondin-1, serum amyloid A, lipopolysaccharides, oxidized LDL (low density lipoprotein), fatty acids, apoptotic cell surfaces, and microparticles (reviewed in 27 ). CD36 has been shown to play a role in innate immune cell activation and renal cell injury. 25, 43 Activation of CD36 by oxidized LDL, in cooperation with the TLR4 (toll-like receptor 4) and TLR6 heterodimer, primes macrophages for IL-1β (interleukin 1β) production. 28 Palmitic acid increased CD36 expression, lipid uptake, leading to podocyte apoptosis. 42 Plasminogen stimulation of podocytes increases ROS generation that promotes ET-1 synthesis and CD36 expression and subsequent increased intracellular cholesterol uptake followed by podocyte apoptosis. 26, 42 As well, activation of CD36 expressed in macrophages and proximal tubular cells could potentiate an inflammatory signaling loop involving these cells and their associated macrophages. 25 Accordingly, we demonstrated that the fraction of nonimmune renal cells expressing CD36 was highly correlated with the fraction of infiltrating immune cells. 25 This may also occur in humans because increased CD36 expression has been reported in renal tubules and glomeruli of patients with diabetic nephropathy and hyperlipidemia. 42 Interestingly, atrasentan treatment reversed the increase in KIM-1 expression and reduced immune cell infiltration and kidney nonimmune CD36-expressing cells. Altogether, these results indicate that eET-1 plays an important role in the development of kidney injury.
In conclusion, we demonstrate that long-term induction of endothelium-restricted human ET-1 overexpression caused sustained BP rise, small artery stiffening and endothelial dysfunction, and early renal damage, which were reversed or reduced by 2-week treatment with the ET A receptor antagonist atrasentan.
Limitations
The present study did not examine whether 3-month induction of human eET-1 overexpression in mice alters renal function. ET receptor expression was determined in the renal cortex and medulla. Changes in vascular ET receptor expression could be masked by ET receptors expressed in renal tubules. It would be interesting to determine whether 3-month induction of human eET-1 overexpression causes an elevation in CD36 expression in podocytes or tubular epithelial cells. This could play an important role in rendering the mice more susceptible to a second hit.
Perspectives
Hypertension is the leading risk factor for global burden of disease. 44 This novel model of inducible endothelial-restricted human ET-1 overexpression devoid of developmental confounding effects will facilitate understanding the role of ET-1 in the pathophysiology of hypertension. This study adds to a substantial body of evidence showing that ET A receptor antagonists could be beneficial in hypertension and other diseases associated with renal inflammation, particularly in patients with difficult-to-control or resistant hypertension.
